Medtech company Onkos Surgical received 510(k) clearance from the FDA for its antibacterial-coated orthopedic implants.
Onkos Surgical’s ELEOS Proximal Tibia with NanoCept Antibacterial Technology prevents intraoperative bacterial contamination during orthopedic implant procedures, according to an Oct. 21 news release from the company.
In preclinical studies, the technology had a 99.999% kill rate of bacteria that are commonly found in operating room environments.
The implants earned the FDA’s De Novo approval in April 2024.
